Evidence map›Paper›PMID 36503070›Full record

ArticleJournal of controlled release : official journal of the Controlled Release Society2023

Nanocurcumin combined with insulin alleviates diabetic kidney disease through P38/P53 signaling axis.

Raghu Ganugula, Nikhil K Nuthalapati, Subhash Dwivedi, Dianxiong Zou, Meenakshi Arora, Richard Friend, David Sheikh-Hamad, Rita Basu, M N V Ravi Kumar

Open access · greenAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of controlled release : official journal of the Controlled Release Society, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.

0numbers the graph read from it
0cells of the map it votes in
20citing papers in PubMed
2.2field-weighted citation impact, top 12% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

20 citing papers in PubMed, 29 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Review
  5. Article
  6. Article
  7. Review
  8. Review
  9. Article
  10. Article
  11. Review
  12. Article
  13. Review
  14. Review
  15. Article
  16. Review
  17. Article
  18. Review
  19. Article
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 3 institutions in 1 country.

Raghu GanugulaThe Center for Convergent Bioscience and Medicine (CCBM), The University of Alabama, Tuscaloosa, AL, USA; College of Community Health Sciences, The University of Alabama, Tuscaloosa, AL, USA; Department of Biological Sciences, The University of Alabama, Tuscaloosa, AL, USA; Alabama Life Research Institute, The University of Alabama, Tuscaloosa, AL, USA.
Nikhil K NuthalapatiThe Center for Convergent Bioscience and Medicine (CCBM), The University of Alabama, Tuscaloosa, AL, USA; College of Community Health Sciences, The University of Alabama, Tuscaloosa, AL, USA.
Subhash DwivediThe Center for Convergent Bioscience and Medicine (CCBM), The University of Alabama, Tuscaloosa, AL, USA; College of Community Health Sciences, The University of Alabama, Tuscaloosa, AL, USA.
Dianxiong ZouThe Center for Convergent Bioscience and Medicine (CCBM), The University of Alabama, Tuscaloosa, AL, USA; College of Community Health Sciences, The University of Alabama, Tuscaloosa, AL, USA.
Meenakshi AroraThe Center for Convergent Bioscience and Medicine (CCBM), The University of Alabama, Tuscaloosa, AL, USA; College of Community Health Sciences, The University of Alabama, Tuscaloosa, AL, USA; Department of Biological Sciences, The University of Alabama, Tuscaloosa, AL, USA; Alabama Life Research Institute, The University of Alabama, Tuscaloosa, AL, USA.
Richard FriendCollege of Community Health Sciences, The University of Alabama, Tuscaloosa, AL, USA.
David Sheikh-HamadDivision of Nephrology and Selzman Institute for Kidney Health, Department of Medicine, Baylor College of Medicine, Houston, TX, USA; Center for Translational Research on Inflammatory Diseases, Michael E. Debakey Veterans Affairs Medical Center, Houston, TX, USA.
Rita BasuDivision of Endocrinology, Center of Diabetes Technology, University of Virginia School of Medicine, Charlottesville, VA, USA.
M N V Ravi KumarThe Center for Convergent Bioscience and Medicine (CCBM), The University of Alabama, Tuscaloosa, AL, USA; College of Community Health Sciences, The University of Alabama, Tuscaloosa, AL, USA; Department of Biological Sciences, The University of Alabama, Tuscaloosa, AL, USA; Alabama Life Research Institute, The University of Alabama, Tuscaloosa, AL, USA; Department of Pharmaceutical Sciences, Irma Lerma Rangel College of Pharmacy, Texas A&M University, College Station, TX, USA; Chemical and Biological Engineering, University of Alabama, Tuscaloosa, AL, USA; Nephrology Research and Training Center, Division of Nephrology, Department of Medicine, University of Alabama at Birmingham, Birmingham, AL, USA; Center for Free Radical Biology, University of Alabama at Birmingham, Birmingham, AL, USA. Electronic address: mnvrkumar@ua.edu.
University of Alabama · USBaylor College of Medicine · USUniversity of Virginia · US

Funding

University of Alabama at Birmingham's Diabetes Research CenterP30DK079626 · NIDDK · UNIVERSITY OF ALABAMA AT BIRMINGHAM · PI BARBARA A GOWER · 2013 to 2026
$19.5M
Systemic anti-inflammatory therapy to prevent or delay diabetic cataracts and treat post-surgical inflammationR01EY028169 · NEI · UNIVERSITY OF ALABAMA IN TUSCALOOSA · PI MAJETI, RAVIKUMAR N · 2017 to 2022
$1.9M
Oral delivery of insulin using ligand-directed nanoparticles that do not compete with physiological ligandsR01DK125372 · NIDDK · UNIVERSITY OF ALABAMA IN TUSCALOOSA · PI GANUGULA, RAGHU, MAJETI, RAVIKUMAR N · 2020 to 2023
$1.5M
BLRD VA I01 BX000303NEI NIH HHS R01 EY028169NIDDK NIH HHS P30 DK079626NIDDK NIH HHS R01 DK125372
6 · The paper itself

Abstract

Treatments for diabetic kidney disease (DKD) mainly focus on managing hyperglycemia and hypertension, but emerging evidence suggests that inflammation also plays a role in the pathogenesis of DKD. This 10-week study evaluated the efficacy of daily oral nanoparticulate-curcumin (nCUR) together with long-acting insulin (INS) to treat DKD in a rodent model. Diabetic rats were dosed with unformulated CUR alone, nCUR alone or together with INS, or INS alone. The progression of diabetes was reflected by increases in plasma fructosamine, blood urea nitrogen, creatinine, bilirubin, ALP, and decrease in albumin and globulins. These aberrancies were remedied by nCUR+INS or INS but not by CUR or nCUR. Kidney histopathological results revealed additional abnormalities characteristic of DKD, such as basement membrane thickening, tubular atrophy, and podocyte cytoskeletal impairment. nCUR and nCUR+INS mitigated these lesions, while CUR and INS alone were far less effective, if not ineffective. To elucidate how our treatments modulated inflammatory signaling in the liver and kidney, we identified hyperactivation of P38 (MAPK) and P53 with INS and CUR, whereas nCUR and nCUR+INS deactivated both targets. Similarly, the latter interventions led to significant downregulation of renal NLRP3, IL-1β, NF-ĸB, Casp3, and MAPK8 mRNA, indicating a normalization of inflammasome and apoptotic pathways. Thus, we show therapies that reduce both hyperglycemia and inflammation may offer better management of diabetes and its complications.

Indexed as

Diabetes Mellitus, ExperimentalDiabetic NephropathiesHyperglycemiaAnimalsInflammationInsulinKidneyp38 Mitogen-Activated Protein KinasesRatsTumor Suppressor Protein p53Insulinp38 Mitogen-Activated Protein KinasesTumor Suppressor Protein p53BioavailabilityCombination therapyCurcuminDiabetic kidney diseaseInflammasomeInsulinOral deliveryP38(MAPK)/P53 signaling axis

Identifiers

PMID36503070
PMCPMC9904426
OpenAlexW4311448120

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.